Log in

Relevant bibliographies by topics / Inflammatory breast cancer (IBC) / Journal articles

To see the other types of publications on this topic, follow the link: Inflammatory breast cancer (IBC).

Journal articles on the topic 'Inflammatory breast cancer (IBC)'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Inflammatory breast cancer (IBC).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lynce, Filipa. "Abstract ED4-3: Inflammatory Breast Cancer." Cancer Research 83, no. 5_Supplement (2023): ED4–3—ED4–3. http://dx.doi.org/10.1158/1538-7445.sabcs22-ed4-3.

Full text

Abstract:

Abstract Inflammatory Breast Cancer (IBC) has an incidence of 1-5% among all breast cancers diagnosed within the USA, yet it accounts for a disproportionately high rate of mortality, leading to up to 10% of all breast cancer related deaths. Although IBC can present with any receptor status in terms of estrogen, progesterone, and human epidermal growth factor 2 (HER2), there is a higher proportion of HER2 positive cases compared to non-IBC. Given the distinct difference in outcome, it is important to differentiate IBC from more indolent locally advanced non-IBC with secondary inflammatory featu

APA, Harvard, Vancouver, ISO, and other styles

2

Dushkin, Holly, and Massimo Cristofanilli. "Inflammatory Breast Cancer." Journal of the National Comprehensive Cancer Network 9, no. 2 (2011): 233–41. http://dx.doi.org/10.6004/jnccn.2011.0018.

Full text

Abstract:

Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity, and has made the role of locoregional therapy, including surgery and radiation, critical to continued improvements in this disease. This artic

APA, Harvard, Vancouver, ISO, and other styles

3

Chang, S., A. U. Buzdar, and S. D. Hursting. "Inflammatory breast cancer and body mass index." Journal of Clinical Oncology 16, no. 12 (1998): 3731–35. http://dx.doi.org/10.1200/jco.1998.16.12.3731.

Full text

Abstract:

PURPOSE No studies have investigated the etiology of inflammatory breast cancer (IBC), the most lethal form of breast cancer. Because high body mass index (BMI) is associated with decreased risk of premenopausal breast cancer but increased risk of postmenopausal breast cancer, we evaluated whether high BMI was a risk factor for IBC. PATIENTS AND METHODS In a case-comparison study, we matched by ethnicity and registration date 68 IBC patients treated at The University of Texas M.D. Anderson Cancer Center from 1985 to 1996 with 143 patients with non-IBC and 134 patients with cancer at sites othe

APA, Harvard, Vancouver, ISO, and other styles

4

Wang, Xiaoping, Takashi Semba, Lan Thi Hanh Phi, et al. "Targeting Signaling Pathways in Inflammatory Breast Cancer." Cancers 12, no. 9 (2020): 2479. http://dx.doi.org/10.3390/cancers12092479.

Full text

Abstract:

Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2–4% of breast cancer cases are classified as IBC, but—owing to its high rate of metastasis and poor prognosis—8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting

APA, Harvard, Vancouver, ISO, and other styles

5

Marzogi, Alaa Abdulrahman, Reem Mohammed Noor Kalakattawi, Athal Kamal Filemban, and Amani Mohammad Abbad Alwadei. "A Case Study of an Inflammatory Breast Cancer in Men-lobular Subtype." Journal of Pioneering Medical Sciences 14, no. 1 (2025): 8–14. https://doi.org/10.47310/jpms2025140102.

Full text

Abstract:

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, accounting for 1–5% of all breast malignancies. Male breast cancer is particularly uncommon, comprising less than 1% of all cases and IBC in males presents even greater diagnostic and therapeutic challenges. This case study highlights a 49-year-old Sudanese male diagnosed with inflammatory breast cancer of the lobular subtype. The patient initially presented with a palpable right breast mass and nipple discharge, without characteristic skin changes often associated with IBC. Diagnostic imaging and biopsy confirmed

APA, Harvard, Vancouver, ISO, and other styles

6

Mohamed, Hossam Taha, Valérie Untereiner, Gianfelice Cinque, et al. "Infrared Microspectroscopy and Imaging Analysis of Inflammatory and Non-Inflammatory Breast Cancer Cells and Their GAG Secretome." Molecules 25, no. 18 (2020): 4300. http://dx.doi.org/10.3390/molecules25184300.

Full text

Abstract:

Glycosaminoglycans (GAGs)/proteoglycans (PGs) play a pivotal role in the metastasis of inflammatory breast cancer (IBC). They represent biomarkers and targets in diagnosis and treatment of different cancers including breast cancer. Thus, GAGs/PGs could represent potential prognostic/diagnostic biomarkers for IBC. In the present study, non-IBC MDA-MB-231, MCF7, SKBR3 cells and IBC SUM149 cells, as well as their GAG secretome were analyzed. The latter was measured in toto as dried drops with high-throughput (HT) Fourier Transform InfraRed (FTIR) spectroscopy and imaging. FTIR imaging was also em

APA, Harvard, Vancouver, ISO, and other styles

7

Baker, Jennifer L., John Hegde, Carlie K. Thompson, Minna K. Lee, and Maggie L. DiNome. "Locoregional Management of Inflammatory Breast Cancer." Current Breast Cancer Reports 12, no. 4 (2020): 326–35. http://dx.doi.org/10.1007/s12609-020-00389-6.

Full text

Abstract:

Abstract Purpose of Review Inflammatory breast cancer (IBC) is a biologically aggressive subtype with a high risk for rapid local progression and early distant metastasis. We review the updated data for optimal locoregional management of IBC, including areas of active controversy. Recent Findings Advancements in tri-modality therapies have improved survival among IBC patients in recent years; however, the risk of locoregional and distant recurrence remains high, particularly in triple-negative IBC. Data to support de-escalation of surgery or radiotherapy is limited, and the recommended treatme

APA, Harvard, Vancouver, ISO, and other styles

8

Zhou, Kaiwen, Ying Lin, Mengmeng Zhang, Nan Shao, and Zhen Shan. "Genomic and transcriptomic profiling of inflammatory breast cancers and non-inflammatory breast cancers in Asian women." Journal of Clinical Oncology 41, no. 16_suppl (2023): e12546-e12546. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e12546.

Full text

Abstract:

e12546 Background: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Despite its rare incidence, it accounts for 10% of breast cancer-caused mortality. Previous studies based on NGS have focused on western populations and found no common genomic and transcriptomic difference that could distinguish IBC from non-IBC. Methods: We performed WES on 15 IBC samples and their paired normal blood to identify somatic genomic alterations, copy number variants and large structural variants. RNA-seq was performed on 16 IBC samples to examine the RNA expression, pathway enrichme

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, Zheng, Hui Wang, Xinyuan Ding, Xiaosong Chen, and Kunwei Shen. "A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592093267. http://dx.doi.org/10.1177/1758835920932674.

Full text

Abstract:

Background and aims: Breast cancer-related death is attributable mainly to metastasis. Inflammatory breast cancer (IBC) is an infrequent subtype of breast cancer that shows a relatively high rate of metastasis. In this study, we aimed to compare the metastatic patterns and prognostic outcomes of IBC and non-inflammatory breast cancer (non-IBC). Methods: We extracted data between 2010 and 2014 from the Surveillance, Epidemiology and End Results (SEER) database. The Chi-square test and Fisher’s exact test were used to compare the categorical parameters among different groups. Logistic regression

APA, Harvard, Vancouver, ISO, and other styles

10

Howard, F. "Abstract ED11-01: Is inflammatory breast cancer a genomically different type of breast cancer?" Cancer Research 84, no. 9_Supplement (2024): ED11–01—ED11–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-ed11-01.

Full text

Abstract:

Abstract Inflammatory Breast Cancer (IBC) is a unique and aggressive disease, constituting 2 - 4% of breast cancer diagnoses yet responsible for up to 10% of breast cancer related deaths. IBC remains a clinical diagnosis, without highly specific molecular markers, and the genomic drivers of the disease are incompletely characterized. The overrepresentation of human epidermal growth factor 2 amplification and triple-negative disease within IBC have confounded comparisons between IBC and non-IBC. Nonetheless, some consistent genomic observations have emerged that may begin to explain the charact

APA, Harvard, Vancouver, ISO, and other styles

11

Denu, Ryan A., John M. Hampton, Adam Currey, et al. "Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers." Journal of Cancer Epidemiology 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/7574946.

Full text

Abstract:

Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states. Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (N=170) and 4.9% (N=375), respectively. IBC patients were more likely to have a higher number (P=0.03) and severity (P=0.01) of comorbidities

APA, Harvard, Vancouver, ISO, and other styles

12

Ashraf, Nour, Swellmein Hamdan, Jawad Hameed, and Abdelhady Khaled. "Post burn and bilateral inflammatory breast cancer: Three case reports from one patient." Journal of Gynecological Research and Obstetrics 10, no. 1 (2024): 007–10. http://dx.doi.org/10.17352/jgro.000124.

Full text

Abstract:

Inflammatory Breast Cancer (IBC) is the most aggressive form of primary breast cancer. IBC has an incidence of approximately 2.5 cases per 100,000 women. Malignant neoplasms arising from burn scars are well-known but rarely encountered. The subject was reviewed in a comprehensive publication that reviewed the literature between 1923 and 2007 and found 412 well-documented cases of squamous cell carcinoma (71%), basal cell carcinoma (12%), melanoma (6%), sarcoma (5%), other neoplasms (4%), squamo-basal cell carcinoma (1%), and squamous cell-melanoma (1%). In 2008, two cases were reported by Losa

APA, Harvard, Vancouver, ISO, and other styles

13

Martin, Breonna J., and Kenneth L. van Golen. "A Comparison of Cholesterol Uptake and Storage in Inflammatory and Noninflammatory Breast Cancer Cells." International Journal of Breast Cancer 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/412581.

Full text

Abstract:

Although there are many subtypes of breast cancer, inflammatory breast cancer (IBC) is arguably the deadliest. Research over the past decade has demonstrated that IBC is a distinct entity from other forms of breast cancer. Important risk factors that have been associated with the development of aggressive breast cancers, such as IBC, include obesity and diet, which are evident in the United States, where the overconsumption of high-fat foods continues to contribute to obesity in the nation. Here we investigate differences in cholesterol uptake and storage between IBC, non-IBC, and mammary epit

APA, Harvard, Vancouver, ISO, and other styles

14

Hazra, Aditi, Andrea O’Hara, Kornelia Polyak, et al. "Copy Number Variation in Inflammatory Breast Cancer." Cells 12, no. 7 (2023): 1086. http://dx.doi.org/10.3390/cells12071086.

Full text

Abstract:

Identification of a unique genomic biomarker in de novo inflammatory breast cancer (IBC) may provide an insight into the biology of this aggressive disease. The goal of our study was to elucidate biomarkers associated with IBC. We examined breast biopsies collected from Dana–Farber Cancer Institute patients with IBC prior to initiating preoperative systemic treatment (30 samples were examined, of which 14 were eligible). Patients without available biopsies (n = 1), with insufficient tumor epithelial cells (n = 10), or insufficient DNA yield (n = 5) were excluded from the analysis. Molecular su

APA, Harvard, Vancouver, ISO, and other styles

15

蘇怡芳, 蘇怡芳. "以瀰漫性紅腫為表徵之發炎性乳癌". 台灣專科護理師學刊 10, № 2 (2023): 056–66. http://dx.doi.org/10.53106/2410325x2023121002007.

Full text

Abstract:

<p>臨床上，乳房紅腫常會讓人聯想為乳房發炎性疾病。本案例是一位44歲女性，因右側乳房瀰漫性紅腫約四週未改善就醫，後診斷為右側乳癌第三期，並行右側乳房根除性手術，術後三週，住院計畫做化療，發現白血球升高、右胸壁及右腋下多處復發。考量疾病進展迅速，回溯過去病史、治療過程及病理報告，最後診斷為發炎性乳癌（Inflammatory Breast Cancer, IBC），予以多模式治療後，腫瘤消除。發炎性乳癌相當罕見，沒有特定組織學，易與乳房發炎性疾病及其它局部嚴重晚期乳癌（Locally Advanced Breast Cancer, LABC）混淆。建議臨床同仁，如果乳房有發炎現象，使用抗生素兩週無效時，須將發炎性乳癌列為鑑別診斷並將其特徵謹記於心，以免延誤治療和危害病人生命。</p> <p>&nbsp;</p><p>In clinical practice, breast erythema is often linked to breast inflammatory diseases. The case of this study is a 44-year-old female, who went to the hospital due to diffuse erythema with swelling on th

APA, Harvard, Vancouver, ISO, and other styles

16

Ortiz-Soto, Gabriela, Natalia S. Babilonia-Díaz, Mercedes Y. Lacourt-Ventura, et al. "Metadherin Regulates Inflammatory Breast Cancer Invasion and Metastasis." International Journal of Molecular Sciences 24, no. 5 (2023): 4694. http://dx.doi.org/10.3390/ijms24054694.

Full text

Abstract:

Inflammatory breast cancer (IBC) is one of the most lethal subtypes of breast cancer (BC), accounting for approximately 1–5% of all cases of BC. Challenges in IBC include accurate and early diagnosis and the development of effective targeted therapies. Our previous studies identified the overexpression of metadherin (MTDH) in the plasma membrane of IBC cells, further confirmed in patient tissues. MTDH has been found to play a role in signaling pathways related to cancer. However, its mechanism of action in the progression of IBC remains unknown. To evaluate the function of MTDH, SUM-149 and SU

APA, Harvard, Vancouver, ISO, and other styles

17

Xie, Xuemei, Jangsoon Lee, Ganiraju C. Manyam, et al. "LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer." Cancers 17, no. 11 (2025): 1887. https://doi.org/10.3390/cancers17111887.

Full text

Abstract:

Triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) are the most aggressive molecular subtypes of breast cancer. Poor clinical outcomes highlight the pressing need to discover novel targets for the effective treatment of these diseases. LMP7 (β5i/PSMB8), a proteolytic subunit of the immunoproteasome, is implicated in the pathogenesis of multiple myeloma, autoimmune and inflammatory diseases, and inflammation-related cancers. However, the role of LMP7 in TNBC and IBC remains poorly characterized. Here, we evaluated the function of LMP7 in TNBC and IBC using the selective L

APA, Harvard, Vancouver, ISO, and other styles

18

Barkana, Buket D., Ahmed El-Sayed, Rana H. Khaled, et al. "Imaging Modalities in Inflammatory Breast Cancer (IBC) Diagnosis: A Computer-Aided Diagnosis System Using Bilateral Mammography Images." Sensors 23, no. 1 (2022): 64. http://dx.doi.org/10.3390/s23010064.

Full text

Abstract:

Inflammatory breast cancer (IBC) is an aggressive type of breast cancer. It leads to a significantly shorter survival than other types of breast cancer in the U.S. The American Joint Committee on Cancer (AJCC) defines the diagnosis based on specific criteria. However, the clinical presentation of IBC in North Africa (Egypt, Morocco, and Tunisia) does not agree, in many cases, with the AJCC criteria. Healthcare providers with expertise in IBC diagnosis are limited because of the rare nature of the disease. This paper reviewed current imaging modalities for IBC diagnosis and proposed a computer-

APA, Harvard, Vancouver, ISO, and other styles

19

Rosado-Tristani, Diego A., Carlos S. Morales, Esther A. Peterson, and Jose A. Rodríguez-Martínez. "Abstract 2275: Transcription factor landscape cataloguing highlights key insights in inflammatory breast cancer (IBC)." Cancer Research 82, no. 12_Supplement (2022): 2275. http://dx.doi.org/10.1158/1538-7445.am2022-2275.

Full text

Abstract:

Abstract Transcription factors are proteins that bind to DNA in a sequence-specific manner to regulate gene expression for normal cellular functions. Cancers have been shown to have aberrant transcriptional regulation. Therefore, identifying transcription factor landscapes will aid in characterizing complex diseases. As an example, breast cancer has many subtypes that are phenotypically and molecularly distinct. Inflammatory Breast Cancer (IBC) is rare, and the most aggressive form of breast cancer currently known. It is a poorly characterized subtype, and diagnosis often results in poor progn

APA, Harvard, Vancouver, ISO, and other styles

20

Salem, Ayman Maher, Mohamed El-Shinawi, and Salwa Farouk Sabet. "Investigation of telomerase activity in inflammatory and noninflammatory breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): e21055-e21055. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21055.

Full text

Abstract:

e21055 Background: Inflammatory breast cancer (IBC) is an aggressive type of breast cancer disease that has a high incidence in Egypt than western countries. It is characterized by rapid progression, involvement of dermal lymphatic emboli and extensive lymph node involvement. Basic and translational studies needed to define IBC disease biology and identify specific biomarkers have been limited by the paucity of patient samples. Hence, the current study aimed to introduce the telomerase activity level as a novel diagnostic marker for breast cancer and specifically for IBC to be differentiated f

APA, Harvard, Vancouver, ISO, and other styles

21

Paiva, Luiza Darla Aguiar Silva, Ana Carolina Filgueiras Teles, Jeferson dos Santos Souza, et al. "Clinical Significance and Prognostic Value of TLR4 and AGER in Inflammatory Breast Cancer." Cancers 17, no. 13 (2025): 2182. https://doi.org/10.3390/cancers17132182.

Full text

Abstract:

Background/Objectives: Inflammatory breast carcinoma (IBC) is an aggressive and rare neoplasm, accounting for 1–5% of all breast cancers. Toll-like receptor type 4 (TLR4) and Advanced Glycation End Products Receptor (AGER/RAGE) have been implicated in breast cancer, and have been shown to promote tumor growth, metastasis, and resistance to therapy by modulating the tumor microenvironment and inflammatory pathways. However, the role of TLR4 and AGER in IBC has not been elucidated. Methods: TLR4 and AGER immunofluorescence expression were evaluated in 27 IBC and 24 non-IBC samples. The expressio

APA, Harvard, Vancouver, ISO, and other styles

22

Balema, Wintana, Savitri Krishnamurthy, Alison Lawrence, et al. "Abstract P2-26-15: CCR7 expression in Inflammatory breast cancer." Cancer Research 83, no. 5_Supplement (2023): P2–26–15—P2–26–15. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-26-15.

Full text

Abstract:

Abstract Background: Inflammatory breast cancer is an aggressive breast cancer characterized by florid congestion of lymphovascular spaces by tumor emboli. CCR7 is an immune cell receptor that mediates traffic of immune cells into lymphatics that can be expressed on tumor cells. An RNA-seq screen of tumor promoting mammary glands in mice identified CCR7 as an upregulated signal in mammary glands that promoted IBC-like skin invasion. We examined the expression of CCR7 in IBC cell lines and patients to determine the prevalence of this receptor in IBC. Methods: Protein lysates from IBC and non-IB

APA, Harvard, Vancouver, ISO, and other styles

23

Van Laere, S. J., I. Van der Auwera, G. G. Van den Eynden, et al. "Confirmation of the distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene expression analysis." Journal of Clinical Oncology 25, no. 18_suppl (2007): 21055. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.21055.

Full text

Abstract:

21055 Background: We have shown with cDNA microarrays that inflammatory breast cancer (IBC) and non-IBC are distinct biological entities. The purpose of this study was to confirm our previous results using Affymetrix chips. Methods: RNA was extracted from 19 IBC samples and 42 non-stage matched non-IBC samples. RNA was hybridized onto Affymetrix HG U133 Plus 2.0 chips. Gene expression data were normalized using GCRMA and genes with a gene expression of at least 250 in 50% of the cases were filtered in. Hierarchical clustering and principle component analysis was executed. Identification of the

APA, Harvard, Vancouver, ISO, and other styles

24

Santiago-Sánchez, Ginette S., Ricardo Noriega-Rivera, Eliud Hernández-O’Farrill, et al. "Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors." International Journal of Molecular Sciences 22, no. 16 (2021): 8581. http://dx.doi.org/10.3390/ijms22168581.

Full text

Abstract:

Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival rate of 40%. Thus, targeted and effective therapies against IBC are needed. Here, we proposed Lipocalin-2 (LCN2)—a secreted glycoprotein aberrantly abundant in different cancers—as a plausible target for IBC. In immunoblotting, we observed higher LCN2 protein levels in IBC cells than non-IBC cells, where the LCN2 levels were

APA, Harvard, Vancouver, ISO, and other styles

25

Koch, Regina M., Daniel R. Principe, Jose L. Cataneo, and Ajay Rana. "Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy." Cancers 13, no. 11 (2021): 2543. http://dx.doi.org/10.3390/cancers13112543.

Full text

Abstract:

Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. Despite the efficacy of immunotherapy in other difficult to treat forms of breast cancer, progress for immunotherapy in IBC has been difficult. Though immunotherapy has been under clinical investigation in IBC since the 1970s, few approaches have shown significant therapeutic efficacy, and no immunotherapy regimens are currently used in the treatment of IBC. Here, we provide a comprehensive summary of what is known about the immune composition of IBC tumors, clinical a

APA, Harvard, Vancouver, ISO, and other styles

26

Mohamed, Mona M., Salwa Sabet, Dun-Fa Peng, M. Akram Nouh, Mohamed El-Shinawi, and Wael El-Rifai. "Promoter Hypermethylation and Suppression of Glutathione Peroxidase 3 Are Associated with Inflammatory Breast Carcinogenesis." Oxidative Medicine and Cellular Longevity 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/787195.

Full text

Abstract:

Reactive oxygen species (ROS) play a crucial role in breast cancer initiation, promotion, and progression. Inhibition of antioxidant enzymes that remove ROS was found to accelerate cancer growth. Studies showed that inhibition of glutathione peroxidase-3 (GPX3) was associated with cancer progression. Although the role of GPX3 has been studied in different cancer types, its role in breast cancer and its epigenetic regulation have not yet been investigated. The aim of the present study was to investigate GPX3 expression and epigenetic regulation in carcinoma tissues of breast cancer patients’ in

APA, Harvard, Vancouver, ISO, and other styles

27

Flores-Colon, Marienid, and Pablo E. Vivas-Mejia. "Abstract 1580: LCN2 is a therapeutic target against inflammatory breast cancer." Cancer Research 83, no. 7_Supplement (2023): 1580. http://dx.doi.org/10.1158/1538-7445.am2023-1580.

Full text

Abstract:

Abstract Breast cancer (BC) is the most common cancer type accounting for 12% of annual cancer cases worldwide. In the United States, 30% of the newly diagnosed cancer cases in woman are BC. Inflammatory breast cancer (IBC) is a rare and aggressive subtype of BC that accounts for 1 to 5% of all types of BC. Due to its inflammatory characteristics and the absence of a palpable mass, IBC is usually confounded with a mastitis. Once properly diagnosed, IBC has already metastasized. A high portion of IBC tumors overexpress human epidermal growth factor receptor 2 (HER2). These IBC patients (HER2+)

APA, Harvard, Vancouver, ISO, and other styles

28

Arshad, Anam, and Muhammad Ajmal Dina. "Inflammatory Breast Cancer the hidden threat in oncology: A Narrative review." Pioneer Journal of Biostatistics and Medical Research 2, no. 4 (2024): 41–49. https://doi.org/10.61171/v02.04.86.

Full text

Abstract:

The understanding of inflammatory breast cancer (IBC) has advanced significantly since Dr. Haagensen established the initial diagnostic criteria in 1956 in the United States. Inflammatory breast cancer (IBC) is a rare and high destructive subtype of breast cancer, representing 1% to 6% of all breast cancer identifies, marked with rapid progression and an important tendency for metastasis, the manifesting with inflammatory symptoms in the breast that can lead to misdiagnosis as situations like mastitis. In clinically, diagnosis is based on physical signs like edema, erythema and along with hist

APA, Harvard, Vancouver, ISO, and other styles

29

Faldoni, Flavia Lima Costa, Cláudia Aparecida Rainho, and Silvia Regina Rogatto. "Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives." Cells 9, no. 5 (2020): 1164. http://dx.doi.org/10.3390/cells9051164.

Full text

Abstract:

Evidence has emerged implicating epigenetic alterations in inflammatory breast cancer (IBC) origin and progression. IBC is a rare and rapidly progressing disease, considered the most aggressive type of breast cancer (BC). At clinical presentation, IBC is characterized by diffuse erythema, skin ridging, dermal lymphatic invasion, and peau d’orange aspect. The widespread distribution of the tumor as emboli throughout the breast and intra- and intertumor heterogeneity is associated with its poor prognosis. In this review, we highlighted studies documenting the essential roles of epigenetic mechan

APA, Harvard, Vancouver, ISO, and other styles

30

Hu, Xiaoding, Yun Xiong, Emilly Villodre, et al. "Abstract PO2-24-03: Soluble E-cadherin promotes inflammatory breast cancer tumorigenesis via PDIA4-mediated suppression of ferroptosis." Cancer Research 84, no. 9_Supplement (2024): PO2–24–03—PO2–24–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-24-03.

Full text

Abstract:

Abstract Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer known for its rapid progression and high metastatic potential without known distinctive drivers. Currently, there are no FDA-approved targeted therapies specifically for IBC patients, highlighting the urgent need for novel and effective treatments. Through our investigation of metastatic xenograft IBC sublines, we have identified soluble E-cadherin (sEcad), an extracellular proteolytic fragment of full-length E-cadherin, as a protein associated with IBC tumor progression. We hypothesize that sEcad prom

APA, Harvard, Vancouver, ISO, and other styles

31

Lopez-Aguiar, Alexandra, Julie Stephens, Akia Clark, Sandy Lee, and Ko Un Park. "Time to treatment in inflammatory breast cancer: Experience from a single institution." Journal of Clinical Oncology 41, no. 16_suppl (2023): e13530-e13530. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13530.

Full text

Abstract:

e13530 Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that accounts for nearly 10% of breast cancer caused mortality. With an annual rate between 1-4% per year and 3-year overall survival (OS) of about 65%, timely completion of trimodal treatment including systemic therapy, surgery, and radiation therapy is essential. Prior studies have demonstrated impact of time to treatment on OS of non-IBC patients. The aim of this study was to examine the relationship between the time from diagnosis to treatment and outcomes for patients with IBC. Methods: Cate

APA, Harvard, Vancouver, ISO, and other styles

32

Manai, Maroua, Ines ELBini-Dhouib, Pascal Finetti, et al. "MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer." Cells 11, no. 18 (2022): 2926. http://dx.doi.org/10.3390/cells11182926.

Full text

Abstract:

Inflammatory breast cancer (IBC) is the most pro-metastatic form of breast cancer (BC). We previously demonstrated that protein overexpression of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) protein was associated with shorter survival in IBC patients. MARCKS has been associated with the PI3K/AKT pathway. MARCKS inhibitors are in development. Our objective was to investigate MARCKS, expressed preferentially in IBC that non-IBC (nIBC), as a novel potential therapeutic target for IBC. The biologic activity of MPS, a MARCKS peptide inhibitor, on cell proliferation, migration, invasion,

APA, Harvard, Vancouver, ISO, and other styles

33

Fuentes, Zenaida, Rahul Gopalam, Bianca A. Romo, et al. "Abstract 2100: Novel LIPA targeted therapy for treating inflammatory breast cancer." Cancer Research 84, no. 6_Supplement (2024): 2100. http://dx.doi.org/10.1158/1538-7445.am2024-2100.

Full text

Abstract:

Abstract Background: Inflammatory breast cancer (IBC) is a rare but incredibly aggressive subtype of breast cancer (BC). IBC accounts for 2-4% of all occurrences of breast cancer and results in 7-10% of breast cancer-related deaths. IBC is only partially treatable with current therapies such as chemotherapy, surgery, and radiotherapy. Identification of novel therapeutic targets is urgently required. The main organelle for the synthesis, folding, and modification of proteins is called the endoplasmic reticulum (ER). Since elevated basal ER stress (ERS) is usually found in many cancers including

APA, Harvard, Vancouver, ISO, and other styles

34

Kharel, Zeni, Omar P. Nemer, Wang Xi, et al. "Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report." Breast Disease 41, no. 1 (2022): 255–60. http://dx.doi.org/10.3233/bd-210041.

Full text

Abstract:

Inflammatory breast cancer (IBC) is a rare variety of breast cancer accounting for two percent of breast cancer diagnoses in the United States. It is characterized by peau d’orange, breast edema and erythema on physical examination and dermal lymphatic invasion by tumor emboli on histological examination. Micrometastases to lymphatics and bone marrow at the time of diagnosis and angiogenic properties of IBC explain the high propensity of this cancer to relapse and metastasize, its aggressiveness and poor prognosis. Preoperative sequential anthracycline and taxane (plus trastuzumab and pertuzum

APA, Harvard, Vancouver, ISO, and other styles

35

Romo, Bianca, Zenaida Fuentes, Lois Randolph, et al. "Abstract 5986: Significance of LIF/LIFR axis in the progression of inflammatory breast cancer." Cancer Research 84, no. 6_Supplement (2024): 5986. http://dx.doi.org/10.1158/1538-7445.am2024-5986.

Full text

Abstract:

Abstract Background: Inflammatory breast cancer (IBC) is a rare form of locally progressed breast cancer. Even though it is uncommon, IBC accounts for 7% of breast cancer deaths. There is a critical need for novel therapeutic targets to develop new therapeutics. IBC is more common in young women. Altered levels of growth factors, and cytokine signaling are suspected to play a role in the progression of IBC. Leukemia inhibitory factor (LIF) is the most pleiotropic member of the interleukin-6 family of cytokines. LIF and its receptor LIFR have been linked to the progression of many cancers inclu

APA, Harvard, Vancouver, ISO, and other styles

36

Anderson, William F., Kenneth C. Chu, and Shine Chang. "Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?" Journal of Clinical Oncology 21, no. 12 (2003): 2254–59. http://dx.doi.org/10.1200/jco.2003.07.082.

Full text

Abstract:

Purpose: Inflammatory breast carcinoma (IBC) and noninflammatory locally advanced breast carcinoma (LABC) are both associated with poor prognosis; however, whether they are distinct clinicopathologic entities remains controversial. Materials and Methods: To determine whether IBC and LABC were different, we compared tumor characteristics, prognosis, and age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program. An age of 50 years served as a surrogate marker for menopause. Results: Younger age at diagnosis, poorer tumor grade, and negative estrogen receptor

APA, Harvard, Vancouver, ISO, and other styles

37

Priedigkeit, Nolan, Beth Harrison, Melissa Hughes, et al. "Abstract PO1-14-10: Comprehensive clinicogenomic characterization of inflammatory breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO1–14–10—PO1–14–10. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-14-10.

Full text

Abstract:

Abstract BACKGROUND: Inflammatory breast cancer (IBC) is a rare type of breast cancer associated with a unique clinical presentation and overall poor outcomes, recognized as a distinct category by the AJCC staging system. The biological mechanisms driving the IBC phenotype are relatively undefined—partially due to a lack of comprehensive, large-scale genomic studies and limited clinical cohorts. Here, we report one of the largest, subtype-informed clinicogenomic characterizations of IBC to date. METHODS: A retrospective analysis of 2457 patients with metastatic breast cancer who underwent targ

APA, Harvard, Vancouver, ISO, and other styles

38

Alexios-Fotios, Mentis, Zervoudis Stefanos, Papadopoulos Georgios, et al. "Case series of inflammatory breast cancer in two Greek hospitals: our experience and critical appraisal." REVIEW CLINICAL PHARMACOLOGY AND PHARMACOKINETICS, INTERNATIONAL EDITION 35, no. 3 (2023): 95–102. https://doi.org/10.5281/zenodo.10048312.

Full text

Abstract:

Inflammatory breast cancer (IBC) represents a very aggressive type of locally advanced cancer. Because of its rarity, management of IBC appears heterogeneous; thus, reporting experiences from different clinics can be helpful. Fourteen female patients with IBC in two clinics of Greek hospitals were included in this case series study. The type of surgery performed in the eight patients that underwent surgery was modified radical mastectomy after neoadjuvant chemotherapy. Moreover, lymph node excision (level one and two) was performed in all (<i>n</i>=14) patients; all but one patients had positi

APA, Harvard, Vancouver, ISO, and other styles

39

Richard, François, Maxim De Schepper, Marion Maetens, et al. "Abstract P3-08-07: Comparison of the genomic alterations in metastatic inflammatory and non-inflammatory breast cancer." Cancer Research 82, no. 4_Supplement (2022): P3–08–07—P3–08–07. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-08-07.

Full text

Abstract:

Abstract Background:. Inflammatory breast cancer (IBC) represents a rare (~1-5% of all breast cancers, BC) and particularly aggressive type of BC, accounting for roughly 10% of BC-related mortality annually. So far IBC has been mainly characterized at the genomic level using samples from the primary tumor. Here, using publicly available data from two large cohorts, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC to alterations in samples of patients with metastatic non-IBC. Patients and methods:. We retrieved publicly available clinical a

APA, Harvard, Vancouver, ISO, and other styles

40

Lønning, P. E. "Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer." Breast Cancer Online 9, no. 1 (2006): 1–3. http://dx.doi.org/10.1017/s1470903106004731.

Full text

Abstract:

Citation of original article:F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, N. Cervera, C. Tarpin,et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.Cancer Research2005;65(6): 2170–8.Abstract of the original articleBreast cancer is a heterogeneous disease. Comprehensive gene expression profiles obtained using DNA microarrays have revealed previously indistinguishable subtypes of non-inflammatory breast cancer (NIBC) related to different features of mammary epithelial biology and significantly associated with survival. Inflammatory breast c

APA, Harvard, Vancouver, ISO, and other styles

41

Anstine, Lindsey, Alexandra Erwin, Hosea Baker, et al. "Abstract P4-06-13: Empowering the clinician and patient communities through the development of an accessible, online tool to support diagnosis of Inflammatory Breast Cancer (IBC)." Clinical Cancer Research 31, no. 12_Supplement (2025): P4–06–13—P4–06–13. https://doi.org/10.1158/1557-3265.sabcs24-p4-06-13.

Full text

Abstract:

Abstract Inflammatory Breast Cancer (IBC) is a rare and highly aggressive form of advanced breast cancer. Compared to other breast cancers, IBC is uniquely characterized by skin changes and breast swelling often resembling a breast infection. Additionally, IBC is largely a subjective, clinical diagnosis that is challenging to identify. These issues are further potentiated by a general lack of awareness in the clinical and patient communities, further contributing to delays in diagnosis and treatment. Together, these circumstances contribute to poorer outcomes for people with IBC, who have a 5-

APA, Harvard, Vancouver, ISO, and other styles

42

Courtois, Elise, William Flynn, Santhosh Sivajothi, et al. "Abstract P1-24-04: Spatially resolved cell type heterogeneity uncovers the distinct biology of inflammatory breast cancer." Cancer Research 82, no. 4_Supplement (2022): P1–24–04—P1–24–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-24-04.

Full text

Abstract:

Abstract Inflammatory breast cancer (IBC) is the most lethal form of breast cancer due to rapid progression, distinct morbidity due to pain, swelling, infection and eventual death. It accounts for 10% of all breast cancer caused deaths despite being only 2-4% of all breast cancer diagnosis. Histopathologically, scattered tumor emboli and dermal lymphatic invasion are typical histopathological findings of IBC, shown in about 75% of all IBC cases. However, the etiology of this disease remains largely unknown and its diagnostic difficult to establish.Using single cell transcriptomics, we profiled

APA, Harvard, Vancouver, ISO, and other styles

43

Low, Jennifer A., Arlene W. Berman, Seth M. Steinberg, David N. Danforth, Marc E. Lippman, and Sandra M. Swain. "Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy." Journal of Clinical Oncology 22, no. 20 (2004): 4067–74. http://dx.doi.org/10.1200/jco.2004.04.068.

Full text

Abstract:

Purpose To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy. Patients and Methods Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC). Patients were treated to best response with cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen. Patients with

APA, Harvard, Vancouver, ISO, and other styles

44

Faldoni, Flávia L. C., Rolando A. R. Villacis, Luisa M. Canto, et al. "Inflammatory Breast Cancer: Clinical Implications of Genomic Alterations and Mutational Profiling." Cancers 12, no. 10 (2020): 2816. http://dx.doi.org/10.3390/cancers12102816.

Full text

Abstract:

Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer whose molecular basis is poorly understood. We performed a comprehensive molecular analysis of 24 IBC biopsies naïve of treatment, using a high-resolution microarray platform and targeted next-generation sequencing (105 cancer-related genes). The genes more frequently affected by gains were MYC (75%) and MDM4 (71%), while frequent losses encompassed TP53 (71%) and RB1 (58%). Increased MYC and MDM4 protein expression levels were detected in 18 cases. These genes have been related to IBC aggressiveness, and MDM4 is a

APA, Harvard, Vancouver, ISO, and other styles

45

Peterson-Peguero, Esther A., Keishla Rodriguez-Martir, Madeline Ganshert, Dalissa Negron-Figueroa, and Ayeisha N. Colon-Ortiz. "Abstract 3171: The effect of estrogen and phytoestrogens in Inflammatory breast cancer." Cancer Research 84, no. 6_Supplement (2024): 3171. http://dx.doi.org/10.1158/1538-7445.am2024-3171.

Full text

Abstract:

Abstract Inflammatory breast cancer is an aggressive and lethal type of breast cancer. Frequently, this cancer is diagnosed in an advanced stage with metastasis. IBC diagnosis is associated with a worse survival rate than other types of breast cancer. The presence of dermal and stromal tumor emboli blocking the lymphatic vessels under the skin is considered a hallmark of IBC and assumed to be responsible for the high metastatic behavior and aggressiveness of IBC disease. To this date, there are no effective targeted therapeutics, especially for those patients that account for approximately 20-

APA, Harvard, Vancouver, ISO, and other styles

46

Santacruz, Laura L. Mendez, Xavier S. Bittman-Soto, Keishla M. Rodriguez-Martir, Jesus M. Padilla Escalona, Esther Peterson, and Carmen Maldonado-Vlaar. "Abstract 5673: The role of NMDA receptors subunits in the progression of inflammatory breast cancer (IBC)." Cancer Research 82, no. 12_Supplement (2022): 5673. http://dx.doi.org/10.1158/1538-7445.am2022-5673.

Full text

Abstract:

Abstract Inflammatory Breast Cancer (IBC) has a 73% incidence of metastasis to the brain as compared to other cancer types like breast, lung, and bone cancer. Previous research showed that tumor cells from different breast cancer subtypes (-HR/-HER2) and (-HR/+ HER2) have a high incidence of crossing the blood-brain barrier and inducing increased expression of glutamate receptors NMDA subunits (NMDAR1 and NMDR2) in the brain. IBC is the most aggressive and rare type of breast cancer. The absence of a solid tumor is replaced by swelling, redness, and skin changes, resulting in many cases in mis

APA, Harvard, Vancouver, ISO, and other styles

47

Gao, Tianyuan, and Fang Shao. "Risk factors and prognostic factors for inflammatory breast cancer with bone metastasis: A population-based study." Journal of Orthopaedic Surgery 29, no. 2 (2021): 230949902110001. http://dx.doi.org/10.1177/23094990211000144.

Full text

Abstract:

Purpose: Inflammatory breast cancer (IBC) is a rare type of breast cancer with poor prognosis. IBC patients with bone metastasis (BM) often suffer from many complications. This study was performed to identify risk factors with strong capability of predicting high BM risk for IBC patients and find prognostic factors for those patients. Methods: The Surveillance, Epidemiology and End Results (SEER) database was used to collect the clinicopathological and survival information of IBC patients. 966 IBC patients diagnosed between 2010 and 2015 were included to study the risk factors for developing B

APA, Harvard, Vancouver, ISO, and other styles

48

Hoang Huynh, Nhung Le, Chau Anh Nguyen, and Phong Hoang. "Revealing the Aspects of Inflammatory Breast Cancer: From Potential Dangers to Therapeutic Strategies." Fusion of Multidisciplinary Research, An International Journal 5, no. 1 (2024): 579–91. https://doi.org/10.63995/synr8701.

Full text

Abstract:

It provides a comprehensive exploration of inflammatory breast cancer (IBC), a rare and aggressive form of breast cancer characterized by rapid onset and distinctive clinical features. IBC poses significant challenges in early detection and treatment due to its aggressive nature and propensity for metastasis. The article elucidates the clinical presentation, diagnostic criteria, and underlying molecular mechanisms that distinguish IBC from other breast cancer subtypes. The research investigates current therapeutic approaches and emerging strategies tailored specifically for IBC. These include

APA, Harvard, Vancouver, ISO, and other styles

49

Cupp, Julie A., Diane Liu, Yu Shen, et al. "Factors influencing survival in inflammatory breast cancer." Journal of Clinical Oncology 32, no. 26_suppl (2014): 136. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.136.

Full text

Abstract:

136 Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer associated with poor prognosis, characterized by rapidly growing mass, skin changes, and regional adenopathy. The objective of this study was to determine if delay in treatment influenced survival in IBC patients. Methods: A prospective IBC database identified 93 women with stage III IBC who received care at MD Anderson from 2007 - 2012 and were retrospectively reviewed. All patients received neoadjuvant chemotherapy followed by surgery, unless progression of disease was noted, and postmastectomy ra

APA, Harvard, Vancouver, ISO, and other styles

50

Masuda, Hiroko, Keith Baggerly, Ying Wang, et al. "Molecular comparison of human triple-negative inflammatory breast cancer (TN-IBC) and human triple-negative noninflammatory breast cancer (TN-non-IBC)." Journal of Clinical Oncology 30, no. 15_suppl (2012): 1047. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1047.

Full text

Abstract:

1047 Background: IBC has a poor prognosis because of its high rate of recurrence. There is an urgent need to define the biology of IBC to develop molecular-based targeted therapies for this disease. TNBC has a similar poor prognosis. Recently, Lehmann et al. (JCI, 2011) identified 7 subtypes of TNBC: basal-like (BL) 1 and 2, immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and “unknown.” In light of these findings, we hypothesized that the distribution of TNBC subtypes differs between TN-IBC and TN-non-IBC. Methods: We qualitatively reproduc

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!